Author:
Yanagihara Toyoshi,Hatashima Hikaru,Ogata Hiroaki,Moriuchi Yuki,Ishimatsu Akiko,Otsuka Junji,Taguchi Kazuhito,Moriwaki Atushi,Yoshida Makoto
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada;Hopkins RB;Eur Respir J,2016
2. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11;Raghu G;Lancet Respir Med,2014
3. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial;Naccache JM;Lancet Respir Med,2022
4. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review;Gertz MA;JAMA,2020
5. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association;Kittleson MM;Circulation,2020